RxDoctor Payments Data

Nassir Rostambeigi, MD

Vascular & Interventional Radiology · Minneapolis, MNNPI 1225349822

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (39.1%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Boston Scientific at 46.9% of the total. 2025 is the largest year on record at $8,453, 6.0 times the $1,399 reported in 2019.

$16,120in general payments, 2019–2025

Across 134 payments — averaging $120.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$8K
  • Cook Incorporated$2K
  • Medtronic$1K
  • GE HealthCare$1K
  • Terumo Medical Corporation$964
  • Cook Medical LLC$588
  • plus $2K from 12 others

What the payments were for

  • Consulting fees$5,91337%
  • Travel & lodging$3,81524%
  • Food & beverage$6,30339%
  • Education$901%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,120 in reported general payments places this provider in the 80th percentile of 78 vascular & interventional radiology providers in Minnesota.

See all vascular & interventional radiology providers in Minnesota

Medicare billing

Part B allowed, 2024
$81,593
Medicare patients
199
Services billed
744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxybutynin Chloride11$64

Paid to pharmacies, not to this prescriber.

Other vascular & interventional radiology in Minneapolis

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →